A Phase 1/2 Multicenter, Open-label, Dose Escalation Study Followed by a Randomized, Double-blind Sham-controlled Dose Expansion Study to Evaluate the Safety, Tolerability and Efficacy of ASP2246 in Adult Participants Who Have Motor Dysfunction Associated With Late Subacute to Chronic Ischemic Stroke Due to Supratentorial Perforator Area Infarction
Latest Information Update: 12 Jan 2026
At a glance
- Drugs Vascular disorder therapies (Primary)
- Indications Ischaemic stroke
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
Most Recent Events
- 12 Jan 2026 New trial record